237 related articles for article (PubMed ID: 19041189)
1. Low-dose naltrexone for disease prevention and quality of life.
Brown N; Panksepp J
Med Hypotheses; 2009 Mar; 72(3):333-7. PubMed ID: 19041189
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
Cree BA; Kornyeyeva E; Goodin DS
Ann Neurol; 2010 Aug; 68(2):145-50. PubMed ID: 20695007
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Sharafaddinzadeh N; Moghtaderi A; Kashipazha D; Majdinasab N; Shalbafan B
Mult Scler; 2010 Aug; 16(8):964-9. PubMed ID: 20534644
[TBL] [Abstract][Full Text] [Related]
4. The resolution of inflammation and cancer.
Rodriguez-Vita J; Lawrence T
Cytokine Growth Factor Rev; 2010 Feb; 21(1):61-5. PubMed ID: 20022797
[TBL] [Abstract][Full Text] [Related]
5. The lowdown on low-dose naltrexone.
Shabeeb N
Cutis; 2020 Jan; 105(1):E17-E18. PubMed ID: 32074159
[TBL] [Abstract][Full Text] [Related]
6. [Low dosage naltrexone].
Raknes G; Giverhaug T
Tidsskr Nor Laegeforen; 2011 Aug; 131(15):1415-6. PubMed ID: 21844938
[No Abstract] [Full Text] [Related]
7. [Research on low dosage naltrexone].
Holmøy T
Tidsskr Nor Laegeforen; 2011 Jul; 131(13-14):1277-8. PubMed ID: 21725378
[No Abstract] [Full Text] [Related]
8. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study.
Raknes G; Småbrekke L
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):136-142. PubMed ID: 27670755
[TBL] [Abstract][Full Text] [Related]
9. No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study.
Raknes G; Småbrekke L
BMC Endocr Disord; 2020 Oct; 20(1):151. PubMed ID: 33004044
[TBL] [Abstract][Full Text] [Related]
10. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z; You Y; Griffin N; Feng J; Shan F
Int Immunopharmacol; 2018 Aug; 61():178-184. PubMed ID: 29885638
[TBL] [Abstract][Full Text] [Related]
11. Low Dose Naltrexone in Dermatology.
Jaros J; Lio P
J Drugs Dermatol; 2019 Mar; 18(3):235-238. PubMed ID: 30909326
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.
Trofimovitch D; Baumrucker SJ
Am J Hosp Palliat Care; 2019 Oct; 36(10):907-912. PubMed ID: 30917675
[TBL] [Abstract][Full Text] [Related]
13. The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat.
Häggkvist J; Lindholm S; Franck J
Addict Biol; 2009 Jul; 14(3):260-9. PubMed ID: 19298318
[TBL] [Abstract][Full Text] [Related]
14. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
Brewer C
Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
[No Abstract] [Full Text] [Related]
15. Naltrexone fails to increase pain affect in response to inflammatory pain in a novel escape/avoidance paradigm.
Uhelski ML; Fuchs PN
Physiol Behav; 2009 Sep; 98(3):263-7. PubMed ID: 19505486
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.
Liu WM; Scott KA; Dennis JL; Kaminska E; Levett AJ; Dalgleish AG
Int J Oncol; 2016 Aug; 49(2):793-802. PubMed ID: 27279602
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS; Fishman MA
Curr Pain Headache Rep; 2020 Aug; 24(10):64. PubMed ID: 32845365
[TBL] [Abstract][Full Text] [Related]
18. Opposite effects of opioid blockade on the blood pressure-pain relationship in depressed and non-depressed participants.
Frew AK; Drummond PD
Pain; 2009 Mar; 142(1-2):68-74. PubMed ID: 19167814
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
20. Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?
Tortelly VD; De Mattos T; Fernandes LSA; Nunes BEM; Melo DF
Dermatol Online J; 2019 Aug; 25(8):. PubMed ID: 31553867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
